Related Experiment Video

Updated: Jul 10, 2025

Chromogenic In Situ Hybridization as a Tool for HPV-Related Head and Neck Cancer Diagnosis
06:57

Chromogenic In Situ Hybridization as a Tool for HPV-Related Head and Neck Cancer Diagnosis

Published on: June 14, 2019

10.4K

The potential of PCNA inhibition as a therapeutic strategy in cervical cancer

Sebastian O Wendel1, Jazmine A Snow1, Long Gu2

  • 1Division of Biology, Kansas State University, Manhattan, Kansas, USA.

Journal of Medical Virology
|November 27, 2023
PubMed

Insights

Proliferating cell nuclear antigen (PCNA) inhibition offers a novel therapeutic strategy for cervical cancer, a leading cause of cancer death in women globally. This approach presents potential benefits and drawbacks for improving cervical cancer treatment outcomes.

Area of Science:

  • Oncology
  • Molecular Biology
  • Cancer Therapeutics

Background:

  • Cervical cancer remains a significant global health challenge, particularly for women worldwide.
  • There is a critical need for innovative treatment strategies to combat this deadly malignancy.
  • Current therapeutic options for cervical cancer have limitations, highlighting the demand for novel approaches.

Purpose of the Study:

  • To explore the therapeutic potential of inhibiting proliferating cell nuclear antigen (PCNA) for cervical cancer treatment.
  • To evaluate the advantages and disadvantages of PCNA-inhibiting compounds in the context of cervical cancer.
  • To address the unmet need for novel therapeutic strategies in managing cervical cancer.

Main Methods:

  • Review of existing literature on proliferating cell nuclear antigen (PCNA) and its role in cancer.
  • Analysis of preclinical and clinical data regarding PCNA inhibitors.
  • Discussion of the specific application and challenges of PCNA inhibition in cervical cancer models.

Main Results:

  • Proliferating cell nuclear antigen (PCNA) is a key regulator of DNA replication and repair, making it a promising therapeutic target.
  • PCNA inhibition has demonstrated potential in preclinical models for various cancers, including cervical cancer.
  • Specific compounds targeting PCNA show promise, but their efficacy and safety profiles require further investigation.

Conclusions:

  • PCNA inhibition represents a novel and potentially effective therapeutic avenue for cervical cancer.
  • Further research is warranted to optimize PCNA-targeting agents and assess their clinical utility in cervical cancer patients.
  • Understanding the advantages and disadvantages of PCNA inhibition is crucial for developing next-generation cervical cancer therapies.
Keywords:
chemotherapydisease controlhuman papillomavirusoncogenesisvirus classification

More Related Videos

Evaluation of the Efficacy of the H. pylori Protein HP-NAP as a Therapeutic Tool for Treatment of Bladder Cancer in an Orthotopic Murine Model06:12

Evaluation of the Efficacy of the H. pylori Protein HP-NAP as a Therapeutic Tool for Treatment of Bladder Cancer in an Orthotopic Murine Model

Published on: May 29, 2015

7.3K
Author Spotlight: Exploring the Role of FAM83A in Cervical Cancer04:20

Author Spotlight: Exploring the Role of FAM83A in Cervical Cancer

Published on: February 9, 2024

959

Related Concept Videos

Inhibition of Cdk Activity02:34

Inhibition of Cdk Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
4.8K
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
7.6K
Chemotherapy-Induced Nausea and Vomiting: Neurokinin-1 Receptor Antagonists01:28

Chemotherapy-Induced Nausea and Vomiting: Neurokinin-1 Receptor Antagonists

Neurokinin 1 (NK1) receptors are distributed across the GI tract, vagal afferents, and key CNS regions including the central vomiting center and chemoreceptor trigger zone (CTZ) Chemotherapy agents stimulate enterochromaffin cells in the gastrointestinal (GI) tract to release large amounts of substance P (SP). SP is a neuropeptide released by specific sensory nerves in response to many different stressors, including those in the GI mucosa affected by chemotherapy.  SP binds and activates...
168
Cancer Vaccines01:30

Cancer Vaccines

Cancer treatment vaccines are a rapidly evolving field that offers a promising approach to immunotherapy. Unlike traditional vaccines that prevent diseases, cancer treatment vaccines are designed to treat existing cancers by stimulating the immune system to recognize and attack cancer cells.
Cancer vaccines come in two categories: preventive (prophylactic) and treatment (active). Preventive vaccines, such as the Human Papillomavirus (HPV) vaccine, protect against viruses that cause certain...
376
Tumor Immunotherapy01:27

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
529